Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 9/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478194 | 1.00 | NAMPT (1.00) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL16634691 | 0.87 | NAMPT (0.77) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL16634818 | 0.86 | NAMPT (0.76) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL16645228 | 0.86 | NAMPT (0.75) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL16634834 | 0.86 | NAMPT (0.75) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL17999905 | 0.85 | NAMPT (0.73) | NAMPTTAAR1FLT3CHEK1ACVR1 | |
| SCHEMBL16634820 | 0.83 | NAMPT (0.70) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL16634908 | 0.82 | NAMPT (0.70) | NAMPTALDH1A1KMT2AMEN1TAAR1 | |
| SCHEMBL17969250 | 0.82 | NAMPT (0.70) | NAMPTKMT2AMEN1TAAR1FLT3 | |
| SCHEMBL16645201 | 0.81 | NAMPT (0.68) | NAMPTALDH1A1ACVR1MAPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021102420-A1 | INTERFERON SIGNALING AS A CANCER BIOMARKER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | claimed |
| WO-2020191359-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-09-24 | — | — | WO | claimed |
| EP-3055304-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | Eli Lilly and Company (US) | 2016-08-17 | — | — | EP | claimed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | claimed |
| WO-2015054060-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-04-16 | — | — | WO | claimed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210369681-A1 | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity | UNIV YALE (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3836929-A1 | METHODS OF TREATING LIVER DISEASES | Camp4 Therapeutics Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021102420-A1 | INTERFERON SIGNALING AS A CANCER BIOMARKER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2020191359-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2020-07-02 | — | — | US | disclosed |
| CN-111094581-A | Methods of treating liver disease | 4阵营疗法公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2020037069-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3055304-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | Eli Lilly and Company (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| WO-2015054060-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054060-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | LIPC, PNPLA2, PNLIP | NAMPT 305/4885ALDH1A1 577/4885KMT2A 2662/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | NAMPT 240/4885ALDH1A1 505/4885KMT2A 2571/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | NAMPT 1/4885ALDH1A1 2286/4885KMT2A 727/4885 |
| US-20210369681-A1 | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity | NAMPT, PPM1D, PPM1A | NAMPT 1/4885ALDH1A1 1419/4885KMT2A 460/4885 |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | NAMPT, NAPRT, NNMT | NAMPT 1/4885ALDH1A1 1219/4885KMT2A 257/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | NAMPT 813/4885ALDH1A1 3928/4885KMT2A 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.